{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ABBV",
  "name": "AbbVie Inc.",
  "url": "https://frontierpicks.com/dossiers/ABBV/",
  "json_url": "https://frontierpicks.com/dossiers/ABBV.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "AbbVie's growth rests on Skyrizi and Rinvoq, which more than offset Humira's decline and back 2026 revenue guidance of about $67.6 billion. The 30 October 2026 third-quarter report shows whether both drugs still grow above 20%.",
  "invalidation_trigger": "A daily close below $255, under the early-October closes of $259.93 and $262.82. Separately, a cut to 2026 revenue guidance from about $67.6 billion, or to Skyrizi guidance from $21.7 billion, at the 2026-10-30 report would break the case.",
  "catalyst_date": "2026-10-30",
  "pick": {
    "id": "P-2026-10-01-ABBV",
    "conviction": "MEDIUM",
    "status": "open",
    "opened": "2026-10-01",
    "open_close": 259.93,
    "kill_level": 245,
    "kill_basis": "daily",
    "horizon_end": "2026-12-31",
    "last_date": "2026-10-09",
    "last_close": 276.47,
    "return_pct": 6.36,
    "spy_return_pct": 1.91,
    "excess_pp": 4.45,
    "kill_distance_pct": 12.844897959183687,
    "closed": null,
    "close_reason": null,
    "outcome": null,
    "scoreboard": "https://frontierpicks.com/track-record/"
  },
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "AbbVie expenses acquired in-process research and development as incurred and excludes future such charges from guidance, so EPS guidance falls whenever a deal or milestone books.",
    "Humira, once AbbVie's largest drug, faces US biosimilar competition, and its revenue is still falling steeply each year.",
    "AbbVie guides the Apogee acquisition to dilute adjusted EPS by about $0.46 in 2027, with accretion not expected until 2032.",
    "Epcoritamab is co-developed with Genmab, so AbbVie shares its economics with a partner."
  ],
  "body_markdown": "## Current Thesis\n\nAbbVie's growth comes from Skyrizi and Rinvoq. In the second quarter each grew about 24%, and together they more than offset Humira's decline. The third-quarter report on 2026-10-30 settles the near-term case. It has to show both drugs still growing above 20% and keep the 2026 revenue guidance of about $67.6 billion intact.\n\nThe shares kept climbing after the 2026-10-07 update. They closed at $272.42 on 2026-10-08, a 52-week high on adjusted daily closes, up from $266.69 on 2026-10-06. They are up 10.6% over three months. Two new items arrived. Analysts raised targets again: Morgan Stanley to $310 on 2026-10-07, then JP Morgan to $300 and Cantor Fitzgerald to $290 on 2026-10-08, all with Overweight ratings, according to Benzinga headlines. And on 2026-10-07 the FDA granted two Breakthrough Therapy designations to telisotuzumab adizutecan (Temab-A), AbbVie's c-Met antibody-drug conjugate, in colorectal and lung cancer.\n\nThe 2026-10-05 guidance cut still frames the quarter. AbbVie lowered 2026 adjusted earnings per share (EPS) guidance to $13.76–$13.96 and third-quarter guidance to $3.73–$3.77. Its 8-K ties the cut to a $216 million pre-tax charge for acquired in-process research and development (IPR&D) and milestones, worth $0.11 per share. That charge reflects deal spending and says nothing new about drug sales.\n\nThe narrative is maturing: the Skyrizi and Rinvoq story is widely known, four brokers raised targets in the three sessions from 2026-10-06 to 2026-10-08, and the shares set a new high on 2026-10-08 with no new sales figures since the 2026-07-31 report.\n\n## Bull Case\n\n- **Two immunology drugs carry the growth.** In Q2 2026 Skyrizi grew 24.4% to $5.505 billion and Rinvoq grew 24.5% to $2.525 billion, according to AbbVie's 2026-07-31 release. The company raised 2026 Skyrizi guidance to $21.7 billion the same day.\n- **Analyst targets cluster well above the price.** Scotiabank raised its target to $320 on 2026-10-06, Morgan Stanley to $310 on 2026-10-07, and JP Morgan to $300 and Cantor Fitzgerald to $290 on 2026-10-08. HSBC's target is $315 (2026-09-10) and BofA's is $289 (2026-09-30).\n- **Oncology pipeline adds two fronts.** Temab-A received Breakthrough Therapy designations on 2026-10-07 with bevacizumab in refractory metastatic colorectal cancer and alone in previously treated c-Met-expressing non-squamous lung cancer. On 2026-10-05 epcoritamab plus R-CHOP cut the risk of progression or death by 51% (hazard ratio 0.49) in newly diagnosed diffuse large B-cell lymphoma, AbbVie and Genmab reported.\n- **Rinvoq is close to a new use.** In Phase 3 Viti-Up-1, 55.1% of patients on Rinvoq 15 mg reached a 75% improvement in facial vitiligo at week 76, up from 33.1% at week 48, AbbVie reported on 2026-10-01. The company expects an FDA decision in Q4 2026.\n- **Neuroscience is a second engine.** Neuroscience revenue rose 20.3% to $3.228 billion in Q2 2026. The FDA approved Juvmo (tavapadon) for Parkinson's disease on 2026-09-25, with a US launch set for October 2026.\n- **Defensive rotation favours the shares.** On 2026-10-07, when 9 of 11 S&P sectors fell, health care led the session, according to Benzinga's sector recap.\n\n## Bear Case\n\n- **Deal charges keep cutting EPS guidance.** The 2026-10-05 cut to $13.76–$13.96 followed a 2026-07-31 cut to $13.87–$14.07 from $13.91–$14.11. AbbVie's guidance excludes future IPR&D charges, so each new deal or milestone lowers it again.\n- **Apogee dilutes earnings for years.** AbbVie guides the $10.9 billion Apogee acquisition, closed on 2026-09-03, to reduce adjusted EPS by about $0.46 in 2027, with accretion not expected until 2032.\n- **Humira is still shrinking fast.** Humira revenue fell 35.9% to $756 million in Q2 2026 under US biosimilar competition, per the company's 2026-07-31 release.\n- **Oncology sales are flat to down today.** Oncology revenue fell 1.5% to $1.650 billion in Q2 2026. Temab-A and epcoritamab's frontline use add no sales before regulatory filings and approvals.\n- **The price has run ahead of sales data.** The shares closed at a 52-week high of $272.42 on 2026-10-08 with a 14-day relative strength index (RSI) of 68.4, near the 70 level often read as overbought, and three weeks before the quarterly report.\n- **Federal pricing changes are unquantified.** AbbVie joins the HRSA 340B Rebate Model Pilot from 2027-01-01 for Imbruvica, Linzess and Vraylar, per its 2026-10-02 release, and has given no revenue effect.\n\n## Setup & Price Structure\n\nThe last close was $272.42 on 2026-10-08, which is also the 52-week high on adjusted daily closes. The shares rose from $262.82 on 2026-10-02 to $265.76 on 2026-10-05, $266.69 on 2026-10-06 and $272.42 on 2026-10-08, a gain of about 3.7% in four sessions. The 14-day RSI stood at 68.4 on 2026-10-08.\n\nThe early-October closes of $259.93 and $262.82 mark where the latest climb began. A daily close below $255 would put the shares under that whole range and erase the October advance. The analyst targets cited above run from $289 (BofA) to $320 (Scotiabank).\n\nCrowding is visible in three places: the shares sit at a 52-week high, four brokers raised targets in three sessions, and CNBC's Halftime Report named AbbVie a \"Final Trade\" on three straight days from 2026-09-28. The 2026-10-30 report is the next hard test of that enthusiasm.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-10-30 — Third-quarter 2026 results, before the market opens; call at 8 a.m. Central.** AbbVie guides adjusted EPS of $3.73–$3.77. The report shows whether Skyrizi and Rinvoq still grow above 20% and whether the $67.6 billion revenue and $21.7 billion Skyrizi guidance hold.\n- **~2026-10-31, est. US launch of Juvmo (tavapadon).** AbbVie set the Parkinson's launch for October 2026; it starts sales of a new neuroscience drug.\n- **~2026-12-31, est. FDA decision on Rinvoq for non-segmental vitiligo.** AbbVie guides the decision to Q4 2026; approval adds a new use for one of the two growth drugs.\n\n## What Would Change Our Mind\n\nThe case breaks if the 2026-10-30 report shows Skyrizi or Rinvoq growth slipping below 20%, or if AbbVie cuts 2026 revenue guidance from about $67.6 billion or Skyrizi guidance from $21.7 billion. Either result would mean the two drugs no longer outrun Humira's decline at the pace the shares now price.\n\nA second break would be a further EPS guidance cut tied to weaker sales rather than to deal charges, or third-quarter adjusted EPS below the $3.73 low end. On price, a daily close below $255 would put the shares under the early-October closes of $259.93 and $262.82 and undo the rally that carried them to the 2026-10-08 high.\n\n## Correlation Notes\n\nAbbVie trades with large-cap pharmaceuticals and the defensive sectors. Its October gains came on days when health care and other defensives led: Benzinga's recaps show defensive sectors in the top three on 2026-10-06 and health care leading on 2026-10-07 while 9 of 11 sectors fell. A rotation back toward growth sectors would remove part of that support regardless of AbbVie's own results. Federal drug-pricing actions, including Medicare negotiation and the 340B rebate pilot, affect the whole group at once.",
  "first_seen": "2026-10-01",
  "last_analyzed": "2026-10-09T08:03:06+00:00",
  "last_synthesized": "2026-10-09",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}